J Thorac Dis. 2012 Aug;4(4):390-7. doi: 10.3978/j.issn.2072-1439.2012.07.12.
Lung cancer represents the most common cause of cancer-related mortality in the United States and around the world. DNA topoisomerase I (TOP1) drugs such as irinotecan and topotecan represent a unique class of chemotherapeutic agents that exhibit not only potent cytotoxic effect, but also tumor-selective radiation-sensitizing effect. The mechanism of cytotoxicity and radiation sensitization by TOP1 drugs has been intensely investigated. Modern radiotherapy, aided by improved imaging and treatment delivery technology, is capable of targeting tumors more precisely, while sparing surrounding critical structures. Clinical trials with camptothecin derivatives and radiotherapy have been conducted in lung cancers. Combined modality therapy with TOP1 drugs and radiotherapy offers a new frontier for lung cancer therapy. We review the present state of TOP1-targeted chemotherapy and modern radiotherapy for lung cancer.
肺癌是美国和全球癌症相关死亡的最常见原因。DNA 拓扑异构酶 I（TOP1）药物，如伊立替康和拓扑替康，代表了一类独特的化疗药物，不仅具有强大的细胞毒性作用，而且具有肿瘤选择性的放射增敏作用。TOP1 药物的细胞毒性和放射增敏作用的机制已被深入研究。现代放疗借助改进的成像和治疗输送技术，能够更精确地靶向肿瘤，同时保护周围的关键结构。喜树碱衍生物与放疗联合治疗肺癌的临床试验已经开展。TOP1 药物与放疗联合的综合治疗为肺癌治疗提供了新的前沿领域。我们综述了肺癌的 TOP1 靶向化疗和现代放疗的现状。
